Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Annals of Hematology
|
September 13, 2013
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Sabine Mousset, Dieter Buchheidt, Werner Heinz, et al.
Annals of Hematology
|
September 19, 2003
Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Hermann Einsele, Hartmut Bertz, Jörg Beyer, et al.
The Lancet. Oncology
|
April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Annals of Hematology
|
March 20, 2016
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Alois Gratwohl, Simona Iacobelli, Natalia Bootsman, et al.
Annals of Hematology
|
March 25, 2014
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Ulrike Proetel, Nadine Pletsch, Michael Lauseker, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
The Lancet. Oncology
|
August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Annals of Hematology
|
July 21, 2017
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase
Mohamad Jawhar, Nicole Naumann, Juliana Schwaab, et al.
International Journal of Cancer
|
October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Annals of Hematology
|
September 13, 2013
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Sabine Mousset, Dieter Buchheidt, Werner Heinz, et al.
Annals of Hematology
|
September 19, 2003
Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Hermann Einsele, Hartmut Bertz, Jörg Beyer, et al.
The Lancet. Oncology
|
April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Annals of Hematology
|
March 20, 2016
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Alois Gratwohl, Simona Iacobelli, Natalia Bootsman, et al.
Annals of Hematology
|
March 25, 2014
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Ulrike Proetel, Nadine Pletsch, Michael Lauseker, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
The Lancet. Oncology
|
August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Annals of Hematology
|
July 21, 2017
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase
Mohamad Jawhar, Nicole Naumann, Juliana Schwaab, et al.
International Journal of Cancer
|
October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
Page
of 5